Generic drug introductions impact Walgreens’ July sales
DEERFIELD, Ill. — Walgreens on Friday reported July sales of $5.6 billion, a decrease of 3.7% as compared with the same month in fiscal 2011. Compared with prior months during this calendar year, July sales comparisons were more significantly impacted by an increase in generic drug introductions, Walgreens reported.
July pharmacy sales decreased 5%, while comparable-store pharmacy sales decreased 9.7%. Calendar day shifts positively impacted pharmacy sales in comparable stores by 2.2 percentage points.
Comparable-store pharmacy sales were negatively impacted by 7.1 percentage points due to generic drug introductions in the last 12 months, by 0.2 percentage point due to the product mix of cough, cold and flu drugs and by 10.8 percentage points due to no longer being part of the Express Scripts network. Prescriptions processed by Express Scripts comprised 12.7% of Walgreens prescriptions in July 2011.
As previously announced, Walgreens again will be a part of the Express Scripts network beginning in September.
Pharmacy sales accounted for 63.7% of total sales for the month.
Total front-end sales decreased 0.8%, compared with the same month in 2011, while comparable-store front-end sales decreased 2.4%. Customer traffic in comparable stores decreased 3.8%, while basket size increased 1.4%.
Sales in comparable stores decreased by 7%. The effect of generic drug introductions in the last 12 months negatively impacted total comparable sales by 4.5 percentage points, while calendar day shifts positively impacted total comparable sales by 1.4 percentage points.
Walgreens opened 16 stores during July, including three relocations, and closed one.
TABS Group promotes Bill Laros
SHELTON, Conn. — The TABS Group has promoted one of its senior consultants.
The company said Bill Laros, who joined the company in 2006, has been named partner. Laros, TABS Group founder and president Kurt Jetta said, has been "instrumental" in developing the TABS WorldView service, which integrates and harmonizes syndicated retail sales data from multiple markets and data suppliers. Jetta also noted that Laros "has done an outstanding job in expanding TABS Group reach to such major [consumer packaged goods] players as Mars, Hormel and Pfizer," adding that Laros’ promotion will continue to allow TABS Group to expand further in the CPG industry.
"Our growth is due to innovative marketing approaches, along with our cutting-edge technology and software, including the recent launch of our new TABS WorldView service," Jetta said.
Teva names two new executives
JERUSALEM — Teva Pharmaceutical Industries has named Carlo De Notaristefani as president and CEO of global operations and Aharon "Arik" Yaari as EVP community and institutional affairs, the Israeli drug maker said Thursday.
The company said De Notaristefani and Yaari would report directly to Teva president and CEO Jeremy Levin.
"We are delighted to have Carlo and Arik in these roles," Levin said. "Teva has a long history of bringing affordable medicines to patients around the world. Through its founding days in Israel, the company has prided itself on the people who have contributed to making Teva a leader in both generic and branded medicines."